hotspot -WSS

hotspot

author：entertainment 2025-08-12 06:43:40 - browse：76

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Rock icon Freddie Mercury pre

focus

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

What to expect at HLTH 2023, the health care industry conference

Physician executives need more than on

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Why age limits for politicians are a terrible idea

Pediatricians' group reaffirms support for gender

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Activists slam private health insurers over coverage restrictions

'Cuddling' is just what the doctor ordered for a 200

The high cost of giving birth even with insurance

FDA rejects Alnylam's heart disease treatment over insufficient data

Bright Health sells Medicare Advantage business to Molina

What to expect at HLTH 2023, the health care industry conference

Supreme Court strikes down use of affirmative action

Calls for Trump's election interference trial to be televised part of long debate

Peter Hotez and the public health issue of online harassment

Medical mystery: When an infection after surgery isn’t what it seems

Wikipedia

Special counsel alerts court to Trump’s social media post

Chemotherapy drug shortage eases slightly but still widespread

3 questions for the future of Biden's cancer moonshot

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Pediatricians' group reaffirms support for gender

Prosecutors seek bail revocation for FTX founder Sam Bankman

focus

knowledge

Wikipedia

hotspot